Your search returned 7 results.

Results
	1.	Ten-year audit of melanoma in a central England population. [electronic resource] by Hardwicke, Joseph Brunt, A Murray Rylands, Gwen Rayatt, Sukh Producer: 20111014 In: Acta dermato-venereologica vol. 91 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	2.	Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial. [electronic resource] by Brunt, A Murray Wheatley, Duncan Yarnold, John Somaiah, Navita Kelly, Stephen Harnett, Adrian Coles, Charlotte Goodman, Andrew Bahl, Amit Churn, Mark Zotova, Rada Sydenham, Mark Griffin, Clare L Morden, James P Bliss, Judith M Producer: 20170928 In: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology vol. 120 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	3.	Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. [electronic resource] by Johnston, Stephen Rd Kilburn, Lucy S Ellis, Paul Dodwell, David Cameron, David Hayward, Larry Im, Young-Hyuck Braybrooke, Jeremy P Brunt, A Murray Cheung, Kwok-Leung Jyothirmayi, Rema Robinson, Anne Wardley, Andrew M Wheatley, Duncan Howell, Anthony Coombes, Gill Sergenson, Nicole Sin, Hui-Jung Folkerd, Elizabeth Dowsett, Mitch Bliss, Judith M Producer: 20131104 In: The Lancet. Oncology vol. 14 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	4.	Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. [electronic resource] by Cameron, David Morden, James P Canney, Peter Velikova, Galina Coleman, Robert Bartlett, John Agrawal, Rajiv Banerji, Jane Bertelli, Gianfilippo Bloomfield, David Brunt, A Murray Earl, Helena Ellis, Paul Gaunt, Claire Gillman, Alexa Hearfield, Nicholas Laing, Robert Murray, Nicholas Couper, Niki Stein, Robert C Verrill, Mark Wardley, Andrew Barrett-Lee, Peter Bliss, Judith M Producer: 20170911 In: The Lancet. Oncology vol. 18 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	5.	Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer. [electronic resource] by Poole, Christopher J Earl, Helena M Hiller, Louise Dunn, Janet A Bathers, Sarah Grieve, Robert J Spooner, David A Agrawal, Rajiv K Fernando, Indrajit N Brunt, A Murray O'Reilly, Susan M Crawford, S Michael Rea, Daniel W Simmonds, Peter Mansi, Janine L Stanley, Andrew Harvey, Peter McAdam, Karen Foster, Liz Leonard, Robert C F Twelves, Christopher J Producer: 20061109 In: The New England journal of medicine vol. 355 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	6.	First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer (CRUKE/04/015). [electronic resource] by Agrawal, Rajiv K Alhasso, Abdulla Barrett-Lee, Peter J Bliss, Judith M Bliss, Peter Bloomfield, David Bowen, Joanna Brunt, A Murray Donovan, Ellen Emson, Marie Goodman, Andrew Harnett, Adrian Haviland, Joanne S Kaggwa, Ronald Morden, James P Robinson, Anne Simmons, Sandra Stewart, Alan Sydenham, Mark A Syndikus, Isabel Tremlett, Jean Tsang, Yat Wheatley, Duncan Venables, Karen Yarnold, John R Producer: 20111208 In: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology vol. 100 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)
	7.	2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial. [electronic resource] by Goldhirsch, Aron Gelber, Richard D Piccart-Gebhart, Martine J de Azambuja, Evandro Procter, Marion Suter, Thomas M Jackisch, Christian Cameron, David Weber, Harald A Heinzmann, Dominik Dal Lago, Lissandra McFadden, Eleanor Dowsett, Mitch Untch, Michael Gianni, Luca Bell, Richard Köhne, Claus-Henning Vindevoghel, Anita Andersson, Michael Brunt, A Murray Otero-Reyes, Douglas Song, Santai Smith, Ian Leyland-Jones, Brian Baselga, Jose Producer: 20131017 In: Lancet (London, England) vol. 382 Online resources: Available from publisher's website Availability: No items available. Save to lists Add to cart (remove)